Bauphar SA
5.0 FTEThe score of Bauphar shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +38 % Total assets -8 % Headcount (avg FTE) +39 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Bauphar's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 220,648 € | ||||
| Equity | 326,271 € | ||||
| Cash | 104,592 € | ||||
| EBITDA | 314,665 € | ||||
| Total assets | €1.24m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 19 Jun 2026
- Year ended 31 Dec 2024filed on 11 Jul 2025
- Year ended 31 Dec 2023filed on 24 Jul 2024
- Year ended 31 Dec 2022filed on 06 Jul 2023
- Year ended 31 Dec 2021filed on 27 Jul 2022
Bauphar's financial analysis
- Solvency26.3%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Bauphar
Bauphar's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0878.246.017
- VAT number
- BE0878246017
- Peppol
- Registered · 0208:0878246017 · as of 09 Nov 2026
- Legal form
- SA
- Incorporated
- 22 Dec 2005
- Registered office
- 1430 Rebecq
- Size
- Micro · 5.0 FTE
- Latest accounts
- 2025 · filed on 19 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Bauphar (SA) has been based in Rebecq since 2005, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 220,648 € and equity of 326,271 €; its revenue is not published. With 5.0 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 26.3%, below the median of its sector (41.5%).
Companies similar to Bauphar
Companies in the same business, of comparable size and area, outside its group.
- Apotheek VAN Speybroeck Retail sale of pharmaceutical products Edegem · balance sheet €1.32m
- Pharmacie Debor-Mordant Retail sale of pharmaceutical products Marche-en-Famenne · balance sheet €1.24m
- Apoteek Rigaux Retail sale of pharmaceutical products Merelbeke-Melle · balance sheet €1.25m
- Groenenhoek Retail sale of pharmaceutical products Antwerp · balance sheet €1.25m
- IM Pharma Retail sale of pharmaceutical products Ichtegem · balance sheet €1.24m
- Niemegeers-Engels BV Retail sale of pharmaceutical products Asse · balance sheet €1.23m
- Oostveld - Pharma Retail sale of pharmaceutical products Lievegem · balance sheet €1.26m
- Angophar Retail sale of pharmaceutical products Brussels · balance sheet €1.26m
Frequently asked questions about Bauphar
What is the revenue of Bauphar?
Bauphar files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Bauphar?
In Belgium, the VAT number is the company number prefixed with BE: BE0878246017 for Bauphar, if the company is VAT-registered. Its company number (CBE) is 0878.246.017.
Where is the registered office of Bauphar?
According to the CBE register, the registered office of Bauphar is in 1430 Rebecq.
What is the equity of Bauphar?
At the close of the 2025 financial year, the equity of Bauphar amounts to 326,271 €, a solvency of 26.3% of total assets.
How many people work at Bauphar?
5.0 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Bauphar?
The register lists 5 active mandates at Bauphar. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Bauphar
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →